Nanotechnology Now - Press Release: "Abraxis BioScience Announces Date for 2009 Fourth Quarter Financial Results and Investor Conference Call"

Home > Press > Abraxis BioScience Announces Date for 2009 Fourth Quarter Financial Results and Investor Conference Call

Abstract:
Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, today announced it will release its 2009 fourth quarter financial results before the market opens on Thursday, March 11, 2010. The company also said that senior management will host an investor conference call the same day at 8:30 a.m. PT/11:30 a.m. ET to review the company's financial results.

Abraxis BioScience Announces Date for 2009 Fourth Quarter Financial Results and Investor Conference Call

Los Angeles, CA | Posted on February 24th, 2010

The conference call will be available to interested parties through a live audio webcast at www.abraxisbio.com and www.earnings.com. The call will also be archived and accessible at both sites for six months.

####

About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 39 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.

For more information, please click here

Contacts:
Investor & Media Inquiries
Abraxis BioScience
Maili Bergman
Director Investor Relations & Corporate Communications
310-883-1300

PondelWilkinson Inc.
Rob Whetstone
310-279-5963

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: